Analytical Data
-
Gene name
MICB
- Application
-
Alternative Names
MHC class I polypeptide-related sequence B; MIC-B; PERB11.2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q29980
-
Expression Region
Ala23~Asp309
-
Molecular Weight
36kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MICB (MHC class I polypeptide-related sequence B) is a key molecule implicated in the immune response against malignant cells and viral infections. It is a member of the natural killer (NK) cell receptor ligand family and plays a critical role in the recognition and elimination of stressed or transformed cells by NK cells. Understanding MICB's structure and function is essential for developing novel immunotherapeutic strategies, particularly in cancer treatment. Recent studies have shown that MICB expression can be upregulated in various tumors, making it a potential target for immunotherapy. Research has focused on the generation of recombinant MICB proteins to elucidate their role in immune modulation, assess their interaction with NK cell receptors, and evaluate their efficacy in adopting strategies like CAR-NK cell therapy. Moreover, recombinant MICB proteins can serve as valuable tools for studying the molecular mechanisms that govern NK cell activation and tolerance, thereby advancing our understanding of immune responses in tumor microenvironments. As a result, the study of MICB recombinant proteins holds promise for improving therapeutic outcomes in oncology and infectious disease management.
